Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

3D ultrasound can detect hair follicle changes and disease phases in alopecia areata.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This study found that Baricitinib effectively reduced alopecia severity in adults with severe alopecia areata during a 12-month observation period, especially when initiated in patients with milder baseline conditions and elevated ESR; no serious adverse events were reported.

This study found that modifying adipose-derived stem cells to overexpress the adhesion protein JAM-A increased the adhesion and resilience of dermal papilla cells in the context of androgenic alopecia, potentially facilitating hair regrowth despite challenges such as damage from dihydrotestosterone and macrophages.

In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.

The report aimed to improve health and safety standards in day care by identifying risks and suggesting solutions.

This study concluded that topical psoralen and ultraviolet A photochemotherapy is an effective and safe treatment for alopecia areata, as it produced a good response in 43.8% of patients.

This study in the United Arab Emirates found that alopecia areata significantly impacts patient quality of life and healthcare resource utilization, particularly among those with higher scalp hair loss.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

This article does not contain an abstract and presents no new clinical findings, instead discussing prior cases and literature on infant alopecia universalis and the potential role of topical PUVA therapy.

This report from the seventh AA Research Summit discusses research highlights and sets future priorities for managing alopecia areata.

This study found that the 3' UTR of JAM-A acts as a key competing endogenous RNA that supports dermal papilla cell function and hair follicle regeneration in alopecia areata.

This study developed the Alopecia Areata Children's Quality of Life Index (AAcQLI) to assess quality of life in children with alopecia areata, demonstrating good reliability and validity in initial tests.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

AGA patients have a lower quality of life than AA patients.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

Alopecia areata has a high chance of persisting and relapsing, with a significant risk of total hair loss, especially if it starts in childhood.

Abatacept may help some people with alopecia areata regrow hair.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.

This study suggests that the prevalence of alopecia areata in the US remains similar to high estimates from the 1970s, with significant implications for quality of life.

This study found that individuals with AA have a higher incidence of atopic and autoimmune conditions, suggesting both Th1 and Th2 immune responses may play a role in its development.

This lecture abstract discusses a career driven by a commitment to helping patients with vitiligo and hidradenitis suppurativa but reports no scientific findings.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

This study found that orally administered Annurca apple extract improved hair length, thickness, weight, and density in mice, while also increasing the expression of hair growth-related genes and proteins, suggesting potential as a natural treatment for hair loss.

This review discusses androgenetic alopecia and other types of hair loss in women, but reports no new results; the authors distinguish between AA with and without virilization.